Lin X, Xu Y, Pan X, Xu J, Ding Y, Sun X, et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep. 2020;10:14790.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183: 109119.
Article
PubMed
Google Scholar
Dal Canto E, Ceriello A, Rydén L, Ferrini M, Hansen TB, Schnell O, et al. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26:25–32.
Article
Google Scholar
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227–337.
Article
PubMed
Google Scholar
Spannella F, Giulietti F, Di Pentima C, Sarzani R. Prevalence and control of dyslipidemia in patients referred for high blood pressure: the disregarded “double-trouble” lipid profile in overweight/obese. Adv Ther. 2019;36:1426–37.
Article
PubMed
PubMed Central
Google Scholar
Gerstein HC. Glucose: a continuous risk factor for cardiovascular disease. Diabet Med. 1997;14:25–31.
Article
Google Scholar
Cai X, Zhang Y, Li M, Wu JH, Mai L, Li J, et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ. 2020;370: m2297.
Article
PubMed
PubMed Central
Google Scholar
Gujral UP, Jagannathan R, He S, Huang M, Staimez LR, Wei J, et al. Association between varying cut-points of intermediate hyperglycemia and risk of mortality, cardiovascular events and chronic kidney disease: a systematic review and meta-analysis. BMJ Open Diabetes Res Care. 2021;9: e001776.
Article
PubMed
PubMed Central
Google Scholar
de Simone G, Wang W, Best LG, Yeh F, Izzo R, Mancusi C, et al. Target organ damage and incident type 2 diabetes mellitus: the Strong Heart Study. Cardiovasc Diabetol. 2017;16:64.
Article
PubMed
PubMed Central
Google Scholar
Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson AM, Miftaraj M, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376:1407–18.
Article
PubMed
Google Scholar
Olesen KKW, Madsen M, Egholm G, Thim T, Jensen LO, Raungaard B, et al. Patients with diabetes without significant angiographic coronary artery disease have the same risk of myocardial infarction as patients without diabetes in a real-world population receiving appropriate prophylactic treatment. Diabetes Care. 2017;40:1103–10.
Article
CAS
PubMed
Google Scholar
Katsiki N, Banach M, Mikhailidis DP. Is type 2 diabetes mellitus a coronary heart disease equivalent or not? Do not just enjoy the debate and forget the patient! Arch Med Sci. 2019;15:1357–64.
Article
CAS
PubMed
PubMed Central
Google Scholar
Banach M, Burchardt P, Chlebus K, Dobrowolski P, Dudek D, Dyrbuś K, et al. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci. 2021;17:1447–547.
Article
CAS
PubMed
PubMed Central
Google Scholar
Plana N, Ibarretxe D, Cabré A, Ruiz E, Masana L. Prevalence of atherogenic dyslipidemia in primary care patients at moderate-very high risk of cardiovascular disease. Cardiovascular risk perception. Clin Investig Arterioscler. 2014;26:274–84.
PubMed
Google Scholar
Kaze AD, Santhanam P, Musani SK, Ahima R, Echouffo-Tcheugui JB. Metabolic dyslipidemia and cardiovascular outcomes in type 2 diabetes mellitus: findings from the look AHEAD study. J Am Heart Assoc. 2021;10: e016947.
Article
PubMed
PubMed Central
Google Scholar
Mortensen MB, Nordestgaard BG. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70–100 years: a contemporary primary prevention cohort. Lancet. 2020;396:1644–52.
Article
CAS
PubMed
Google Scholar
Navar-Boggan AM, Peterson ED, D’Agostino RB Sr, Neely B, Sniderman AD, Pencina MJ. Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease. Circulation. 2015;131:451–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Braunwald E. How to live to 100 before developing clinical coronary artery disease: a suggestion. Eur Heart J. 2022;43:249–50.
Article
PubMed
Google Scholar
Ray KK, Reeskamp LF, Laufs U, Banach M, Mach F, Tokgözoğlu LS, et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2022;43:830–3.
Article
CAS
PubMed
Google Scholar
Banach M, Penson PE, Vrablik M, Bunc M, Dyrbus K, Fedacko J, et al. ACS EuroPath Central & South European Countries Project. Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP). Pharmacol Res. 2021;166:105499.
Article
CAS
PubMed
Google Scholar
Ostadal P, Steg PG, Poulouin Y, Bhatt DL, Bittner VA, Chua T, ODYSSEY OUTCOMES Investigators, et al. Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2022;10:330–40.
Article
CAS
PubMed
Google Scholar
Thompson W, Morin L, Jarbøl DE, Andersen JH, Ernst MT, Nielsen JB, et al. Statin discontinuation and cardiovascular events among older people in Denmark. JAMA Netw Open. 2021;4: e2136802.
Article
PubMed
PubMed Central
Google Scholar
Rannanheimo PK, Tiittanen P, Hartikainen J, Helin-Salmivaara A, Huupponen R, Vahtera J, Korhonen MJ. Impact of statin adherence on cardiovascular morbidity and all-cause mortality in the primary prevention of cardiovascular disease: a population-based cohort study in Finland. Value Health. 2015;18:896–905.
Article
PubMed
Google Scholar
Martin-Ruiz E, Olry-de-Labry-Lima A, Ocaña-Riola R, Epstein D. Systematic review of the effect of adherence to statin treatment on critical cardiovascular events and mortality in primary prevention. J Cardiovasc Pharmacol Ther. 2018;23:200–15.
Article
CAS
PubMed
Google Scholar
Giral P, Neumann A, Weill A, Coste J. Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France. Eur Heart J. 2019;40:3516–25.
Article
PubMed
PubMed Central
Google Scholar
Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459–72.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sahebkar A, Kiaie N, Gorabi AM, Mannarino MR, Bianconi V, Jamialahmadi T, et al. A comprehensive review on the lipid and pleiotropic effects of pitavastatin. Prog Lipid Res. 2021;84: 101127.
Article
CAS
PubMed
Google Scholar
Zhang X, Xing L, Jia X, Pang X, Xiang Q, Zhao X, et al. Comparative lipid-lowering/increasing efficacy of 7 statins in patients with dyslipidemia, cardiovascular diseases, or diabetes mellitus: systematic review and network meta-analyses of 50 randomized controlled trials. Cardiovasc Ther. 2020;2020:3987065.
Article
PubMed
PubMed Central
Google Scholar
Seo WW, Seo SI, Kim Y, Yoo JJ, Shin WG, Kim J, et al. Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases. Cardiovasc Diabetol. 2022;21:82.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jeong HS, Hong SJ, Son S, An H, Kook H, Joo HJ, et al. Incidence of new-onset diabetes with 1 mg versus 4 mg pitavastatin in patients at high risk of developing diabetes during a 3-year follow-up. Cardiovasc Diabetol. 2019;18:162.
Article
CAS
PubMed
PubMed Central
Google Scholar
Huang CH, Huang YY, Hsu BR. Pitavastatin improves glycated hemoglobin in patients with poorly controlled type 2 diabetes. J Diabetes Investig. 2016;7:769–76.
Article
CAS
PubMed
PubMed Central
Google Scholar
Teramoto T, Shimano H, Yokote K, Urashima M. Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia. J Atheroscler Thromb. 2009;16:654–61.
Article
CAS
PubMed
Google Scholar
Adams SP, Alaeiilkhchi N, Wright JM. Pitavastatin for lowering lipids. Cochrane Database Syst Rev. 2020;6:CD012735.
PubMed
Google Scholar
Yokote K, Bujo H, Hanaoka H, Shinomiya M, Mikami K, Miyashita Y, et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis. 2008;201:345–52.
Article
CAS
PubMed
Google Scholar
Moroi M, Nagayama D, Hara F, Saiki A, Shimizu K, Takahashi M, et al. Outcome of pitavastatin versus atorvastatin therapy in patients with hypercholesterolemia at high risk for atherosclerotic cardiovascular disease. Int J Cardiol. 2020;305:139–46.
Article
PubMed
Google Scholar
Casula M, Mozzanica F, Scotti L, Tragni E, Pirillo A, Corrao G, Catapano AL. Statin use and risk of new-onset diabetes: a meta-analysis of observational studies. Nutr Metab Cardiovasc Dis. 2017;27:396–406.
Article
CAS
PubMed
Google Scholar
Hagiwara N, Kawada-Watanabe E, Koyanagi R, Arashi H, Yamaguchi J, Nakao K, et al. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. Eur Heart J. 2017;38:2264–76.
Article
CAS
PubMed
PubMed Central
Google Scholar
Miao XY, Liu HZ, Jin MM, Sun BR, Tian H, Li J, et al. A comparative meta-analysis of the efficacy of statin-ezetimibe co-therapy versus statin monotherapy in reducing cardiovascular and cerebrovascular adverse events in patients with type 2 diabetes mellitus. Eur Rev Med Pharmacol Sci. 2019;23:2302–10.
PubMed
Google Scholar
Kim BK, Hong SJ, Lee YJ, Hong SJ, Yun KH, Hong BK, RACING investigators, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022;400(10349):380–90.
Article
CAS
PubMed
Google Scholar
Wang Y, Zhan S, Du H, Li J, Khan SU, Aertgeerts B, et al. Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies. BMJMED. 2022. https://doi.org/10.1136/bmjmed-2022-000134.
Article
Google Scholar
Nakamura A, Sato K, Kanazawa M, Kondo M, Endo H, Takahashi T, Nozaki E. Impact of decreased insulin resistance by ezetimibe on postprandial lipid profiles and endothelial functions in obese, non-diabetic-metabolic syndrome patients with coronary artery disease. Heart Vessels. 2019;34:916–25.
Article
PubMed
Google Scholar
Banach M, Duell PB, Gotto AM Jr, Laufs U, Leiter LA, Mancini GBJ, et al. Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia. JAMA Cardiol. 2020;5:1124–35.
Article
PubMed
Google Scholar
Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020;27:593–603.
Article
PubMed
Google Scholar
Rubino J, MacDougall DE, Sterling LR, Hanselman JC, Nicholls SJ. Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: a randomized clinical trial. Atherosclerosis. 2021;320:122–8.
Article
CAS
PubMed
Google Scholar
Leiter LA, Banach M, Catapano AL, Duell PB, Gotto AM Jr, Laufs U, et al. Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: a post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials. Diabetes Obes Metab. 2022;24:868–80.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wang X, Zhang Y, Tan H, Wang P, Zha X, Chong W, et al. Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol. 2020;19:128.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cicero AFG, Fogacci F, Hernandez AV, Banach M. Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group and the International Lipid Expert Panel (ILEP). Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: a systematic review and meta-analysis. PLoS Med. 2020;17:e1003121.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bays HE, Banach M, Catapano AL, Duell PB, Gotto AM Jr, Laufs U, et al. Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials. J Clin Lipidol. 2020;14:649-659.e6.
Article
PubMed
Google Scholar
Laufs U, Ballantyne CM, Banach M, Bays H, Catapano AL, Duell PB, et al. Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. J Clin Lipidol. 2022;16:286–97.
Article
PubMed
Google Scholar
Zhang J, Tecson KM, Rocha NA, McCullough PA. Usefulness of alirocumab and evolocumab for the treatment of patients with diabetic dyslipidemia. Proc (Bayl Univ Med Cent). 2018;31:180–4.
PubMed
Google Scholar
Colhoun HM, Leiter LA, Müller-Wieland D, Cariou B, Ray KK, Tinahones FJ, et al. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol. Cardiovasc Diabetol. 2020;19:14.
Article
CAS
PubMed
PubMed Central
Google Scholar
Khan SA, Naz A, Qamar Masood M, Shah R. Meta-analysis of inclisiran for the treatment of hypercholesterolemia. Am J Cardiol. 2020;134:69–73.
Article
CAS
PubMed
Google Scholar
Leiter LA, Kallend DG, Koenig W, Landmesser U, Ray KK, Schwartz GG, et al. Efficacy and safety of inclisiran by baseline body mass index: a post hoc pooled analysis of the ORION-9, ORION-10 and ORION-11 phase III randomized controlled trials. Circulation. 2021;144:A11143.
Google Scholar
Talasaz AH, Ho AJ, Bhatty F, Koenig RA, Dixon DL, Baker WL, Van Tassell BW. Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD. Pharmacotherapy. 2021;41:1009–23.
Article
CAS
PubMed
Google Scholar
Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5:941–50.
Article
CAS
PubMed
Google Scholar
Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, ODYSSEY OUTCOMES Committees and Investigators, et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7:618–28.
Article
CAS
PubMed
Google Scholar
Wang X, Wen D, Chen Y, Ma L, You C. PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis. Cardiovasc Diabetol. 2022;21:107.
Article
CAS
PubMed
PubMed Central
Google Scholar
O’Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation. 2022;146:1109–19.
Article
CAS
PubMed
Google Scholar
Averna M, Banach M, Bruckert E, Drexel H, Farnier M, Gaita D, et al. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: a statement from a European Atherosclerosis Society Task Force. Atherosclerosis. 2021;325:99–109.
Article
CAS
PubMed
Google Scholar
Zhu L, Hayen A, Bell KJL. Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study. Cardiovasc Diabetol. 2020;19:28.
Article
PubMed
PubMed Central
Google Scholar
Koopal C, Visseren FLJ, Westerink J, van der Graaf Y, Ginsberg HN, Keech AC. Predicting the effect of fenofibrate on cardiovascular risk for individual patients with type 2 diabetes. Diabetes Care. 2018;41:1244–50.
Article
CAS
PubMed
Google Scholar
Yokote K, Yamashita S, Arai H, Araki E, Matsushita M, Nojima T, et al. Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials. Cardiovasc Diabetol. 2021;20(1):96.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yoshida M, Nakamura K, Miyoshi T, Yoshida M, Kondo M, Akazawa K, et al. Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl/salt-sensitive rats fed a high-salt and high-fat diet. Cardiovasc Diabetol. 2020;19(1):149.
Article
CAS
PubMed
PubMed Central
Google Scholar
KOWA to Discontinue K-877 (Pemafibrate) "PROMINENT" cardiovascular outcomes study. https://www.prnewswire.com/. Accessed 8 Apr 2022.
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22.
Article
CAS
PubMed
Google Scholar
Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090–8.
Article
CAS
PubMed
Google Scholar
Solnica B, Sygitowicz G, Sitkiewicz D, Cybulska B, Jóźwiak J, Odrowąż-Sypniewska G, Banach M. 2020 Guidelines of the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA) on laboratory diagnostics of lipid metabolism disorders. Arch Med Sci. 2020;16(2):237–52.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lorenzatti AJ, Monsalvo ML, López JAG, Wang H, Rosenson RS. Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON. Cardiovasc Diabetol. 2021;20(1):94.
Article
CAS
PubMed
PubMed Central
Google Scholar
Surma S, Romańczyk M, Filipiak KJ. Evinacumab—the new kid on the block. Is it important for cardiovascular prevention? Int J Cardiol Cardiovasc Risk Prev. 2021;11:200107.
Article
PubMed
PubMed Central
Google Scholar
Surma S, Romańczyk M, Filipiak KJ. Angiopoietin-like proteins inhibitors: new horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia. Cardiol J. 2021. https://doi.org/10.5603/CJ.a2021.0006.
Article
PubMed
Google Scholar
Kalantar-Zadeh K, Schwartz GG, Nicholls SJ, Buhr KA, Ginsberg HN, Johansson JO, et al. Effect of apabetalone on cardiovascular events in diabetes, CKD, and recent acute coronary syndrome: results from the BETonMACE randomized controlled trial. Clin J Am Soc Nephrol. 2021;16:705–16.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nurmohamed NS, Ditmarsch M, Kastelein JJP. CETP-inhibitors: from HDL-C to LDL-C lowering agents? Cardiovasc Res. 2021. https://doi.org/10.1093/cvr/cvab350.
Article
PubMed Central
Google Scholar